SG11202100854TA - Intratumor injection formulation - Google Patents
Intratumor injection formulationInfo
- Publication number
- SG11202100854TA SG11202100854TA SG11202100854TA SG11202100854TA SG11202100854TA SG 11202100854T A SG11202100854T A SG 11202100854TA SG 11202100854T A SG11202100854T A SG 11202100854TA SG 11202100854T A SG11202100854T A SG 11202100854TA SG 11202100854T A SG11202100854T A SG 11202100854TA
- Authority
- SG
- Singapore
- Prior art keywords
- injection formulation
- intratumor injection
- intratumor
- formulation
- injection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862746322P | 2018-10-16 | 2018-10-16 | |
PCT/US2019/047079 WO2020081148A1 (en) | 2018-10-16 | 2019-08-19 | Intratumor injection formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100854TA true SG11202100854TA (en) | 2021-05-28 |
Family
ID=70161989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100854TA SG11202100854TA (en) | 2018-10-16 | 2019-08-19 | Intratumor injection formulation |
Country Status (13)
Country | Link |
---|---|
US (1) | US11439586B2 (en) |
EP (1) | EP3866783A4 (en) |
JP (1) | JP2022508807A (en) |
KR (1) | KR20210078505A (en) |
CN (1) | CN111770752A (en) |
AU (1) | AU2019361709A1 (en) |
BR (1) | BR112021005104A2 (en) |
CA (1) | CA3112201A1 (en) |
MX (1) | MX2021004128A (en) |
PH (1) | PH12021550836A1 (en) |
SG (1) | SG11202100854TA (en) |
TW (1) | TW202027740A (en) |
WO (1) | WO2020081148A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11911499B2 (en) | 2019-11-07 | 2024-02-27 | Resurge Therapeutics, Inc. | System and method for prostate treatment |
US11957654B2 (en) | 2022-01-29 | 2024-04-16 | Resurge Therapeutics, Inc. | Treating benign prostatic hyperplasia |
US11602516B1 (en) | 2022-01-29 | 2023-03-14 | Resurge Therapeutics Inc. | Treating benign prostatic hyperplasia |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60239415A (en) * | 1984-05-15 | 1985-11-28 | Nippon Kayaku Co Ltd | Injection containing etoposide |
US5714512A (en) | 1991-07-08 | 1998-02-03 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
US5698582A (en) | 1991-07-08 | 1997-12-16 | Rhone-Poulenc Rorer S.A. | Compositions containing taxane derivatives |
CA2149150C (en) * | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
AU681231B2 (en) * | 1993-12-29 | 1997-08-21 | Intarcia Therapeutics, Inc. | Methods and compositions for the treatment of a host with a cellular proliferative disease |
US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
US6630168B1 (en) * | 1997-02-20 | 2003-10-07 | Biomedicines, Inc. | Gel delivery vehicles for anticellular proliferative agents |
US6979456B1 (en) * | 1998-04-01 | 2005-12-27 | Jagotec Ag | Anticancer compositions |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
US7816398B2 (en) * | 2001-03-23 | 2010-10-19 | Luitpold Pharmaceuticals, Inc. | Fatty alcohol drug conjugates |
US20030099674A1 (en) * | 2001-08-11 | 2003-05-29 | Chen Andrew X. | Lyophilized injectable formulations containing paclitaxel or other taxoid drugs |
EP1435908A4 (en) | 2001-09-13 | 2006-03-15 | Korea Inst Sci & Tech | Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
ITMI20020680A1 (en) * | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | IMPROVED ANTI-TUMOR COMPOSITION BASED ON PACLITAXEL AND METHOD FOR ITS OBTAINING |
SI1585548T1 (en) * | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Compositions and methods of delivery of pharmacological agents |
EP2308467A3 (en) | 2005-06-17 | 2011-06-22 | Hospira Australia Pty Ltd | Liquid pharmaceutical formulations of docetaxel |
CN1923189A (en) * | 2005-08-30 | 2007-03-07 | 孔庆忠 | Taxine kind anti-cancer slow release injection |
US20080039485A1 (en) * | 2006-08-08 | 2008-02-14 | Targetgen Biotechnology Co., Ltd. | Low-dose-long-term pharmaceutical composition comprising camptothecin derivatives for the treatment of cancers |
KR20100023862A (en) | 2007-06-22 | 2010-03-04 | 싸이도우스 엘엘씨. | Solubilized formulation of docetaxel without tween 80 |
AR063111A1 (en) * | 2007-10-03 | 2008-12-30 | Eriochem Sa | A PHARMACEUTICAL FORMULATION OF TAXANO |
CA2721019C (en) * | 2008-04-18 | 2015-09-15 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
EA201170940A1 (en) | 2009-01-16 | 2012-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | CANCER TREATMENT USING BENDAMUSTIN AND ANTI-CD20-ANTIBODY COMBINATION |
CN102048725B (en) | 2009-10-29 | 2014-07-16 | 中国医学科学院药物研究所 | Taxol-cholesterin complex |
CN102370645B (en) * | 2010-08-04 | 2014-07-23 | 山东新时代药业有限公司 | Anticancer drug composition |
AU2011327824B2 (en) * | 2010-11-08 | 2016-06-02 | Cadila Pharmaceuticals Limited | Pharmaceutical composition of taxoids |
BR112015006176B1 (en) | 2012-09-21 | 2023-04-18 | Intensity Therapeutics, Inc | USE OF A THERAPEUTIC AGENT AND AN INTRACELLULAR PERMEATION ENHANCEMENT AGENT |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
CN114767860A (en) | 2016-04-04 | 2022-07-22 | 克里蒂泰克公司 | Solid tumor treatment method |
US20170326232A1 (en) * | 2016-04-15 | 2017-11-16 | Dynavax Technologies Corporation | Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer |
KR20200032092A (en) | 2017-07-17 | 2020-03-25 | 인스티튜트 구스타브 루시 | Water-in-oil emulsion for injection and use thereof |
JP2021534253A (en) | 2018-08-17 | 2021-12-09 | ホスピーラ オーストラリア ピーティーワイ リミテッド | Liquid bendamustine pharmaceutical composition |
-
2019
- 2019-08-19 AU AU2019361709A patent/AU2019361709A1/en active Pending
- 2019-08-19 CN CN201980008778.8A patent/CN111770752A/en active Pending
- 2019-08-19 WO PCT/US2019/047079 patent/WO2020081148A1/en active Application Filing
- 2019-08-19 EP EP19872947.7A patent/EP3866783A4/en active Pending
- 2019-08-19 SG SG11202100854TA patent/SG11202100854TA/en unknown
- 2019-08-19 MX MX2021004128A patent/MX2021004128A/en unknown
- 2019-08-19 US US16/544,146 patent/US11439586B2/en active Active
- 2019-08-19 JP JP2021546181A patent/JP2022508807A/en active Pending
- 2019-08-19 BR BR112021005104-0A patent/BR112021005104A2/en unknown
- 2019-08-19 CA CA3112201A patent/CA3112201A1/en active Pending
- 2019-08-19 KR KR1020217013783A patent/KR20210078505A/en active Search and Examination
- 2019-08-23 TW TW108130185A patent/TW202027740A/en unknown
-
2021
- 2021-04-14 PH PH12021550836A patent/PH12021550836A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN111770752A (en) | 2020-10-13 |
WO2020081148A1 (en) | 2020-04-23 |
JP2022508807A (en) | 2022-01-19 |
KR20210078505A (en) | 2021-06-28 |
US20200113820A1 (en) | 2020-04-16 |
AU2019361709A1 (en) | 2021-04-15 |
MX2021004128A (en) | 2021-06-15 |
CA3112201A1 (en) | 2020-04-23 |
BR112021005104A2 (en) | 2021-06-08 |
EP3866783A1 (en) | 2021-08-25 |
PH12021550836A1 (en) | 2021-11-22 |
EP3866783A4 (en) | 2022-08-03 |
US11439586B2 (en) | 2022-09-13 |
TW202027740A (en) | 2020-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201807942D0 (en) | Pharmaceutical formulation | |
IL282617A (en) | Aerosolisable formulation | |
GB201801614D0 (en) | Formulation | |
IL282523A (en) | Aerosolisable formulation | |
IL282589A (en) | Aerosolisable formulation | |
IL282567A (en) | Aerosolisable formulation | |
IL282461A (en) | Aerosolisable formulation | |
GB201707930D0 (en) | Formulation component | |
IL282546A (en) | Aerosolised formulation | |
ZA202102871B (en) | Pharmaceutical formulation | |
IL282697A (en) | Aerosolisable formulation | |
IL282392A (en) | Aerosolisable formulation | |
GB201816447D0 (en) | Formulation | |
IL282585A (en) | Aerosolised formulation | |
SG11202100854TA (en) | Intratumor injection formulation | |
IL278927A (en) | Pharmaceutical formulation | |
IL284688A (en) | Formulation | |
GB201807312D0 (en) | Formulation | |
IL280138A (en) | Aerosolisable formulation | |
IL277349A (en) | Herbicide formulation | |
GB201913232D0 (en) | Aerosolisable formulation | |
GB201813229D0 (en) | Formulation | |
GB201817866D0 (en) | Aerosolisable formulation | |
GB201809575D0 (en) | Formulation | |
GB2587402B (en) | Formulation |